In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca AZN announced that the European Commission has approved its blockbuster cancer drug, Imfinzi (durvalumab), for a ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Perioperative durvalumab in combination with FLOT leads to significantly improved survival among individuals with resectable gastric and GEJ cancer.

Meanwhile, the NSE Nifty closed 88 points lower (down 0.3%). Bajaj Finserv, L&T, HDFC Bank on the hand, were among the top ...